prikaz prve stranice dokumenta Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
  Preuzmi
PDF 1.37 MB
Znanstveni rad - Pregledni rad
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Cardiovascular Diabetology, 21 (2022), 1; 263. https://doi.org/10.1186/s12933-022-01684-5
Banach, Maciej; Surma, Stanisław; Reiner, Željko; Katsiki, Niki; Penson, Peter E.; Fras, Zlatko; Sahebkar, Amirhossein; Paneni, Francesco; Rizzo, Manfredi; Kastelein, John

Citirajte ovaj rad

Banach, M., Surma, S., Reiner, Ž., Katsiki, N., Penson, P. E., Fras, Z. ... Kastelein, J. (2022). Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022). Cardiovascular Diabetology, 21. (1). doi: 10.1186/s12933-022-01684-5

Banach, Maciej, et al. "Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)." Cardiovascular Diabetology, vol. 21, br. 1, 2022. https://doi.org/10.1186/s12933-022-01684-5

Banach, Maciej, Stanisław Surma, Željko Reiner, Niki Katsiki, Peter E. Penson, Zlatko Fras, Amirhossein Sahebkar, Francesco Paneni, Manfredi Rizzo i John Kastelein. "Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)." Cardiovascular Diabetology 21, br. 1 (2022). https://doi.org/10.1186/s12933-022-01684-5

Banach, M., et al. (2022) 'Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)', Cardiovascular Diabetology, 21(1). doi: 10.1186/s12933-022-01684-5

Banach M, Surma S, Reiner Ž, Katsiki N, Penson PE, Fras Z, i sur.. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022). Cardiovascular Diabetology [Internet]. 28.11.2022. [pristupljeno 06.05.2024.];21(1). doi: 10.1186/s12933-022-01684-5

M. Banach, et al., "Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)", Cardiovascular Diabetology, vol. 21, br. 1, Studeni 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:732007. [Citirano: 06.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:732007
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
AutorMaciej Banach
AutorStanisław Surma
AutorŽeljko Reiner
AutorNiki Katsiki
AutorPeter E. Penson
AutorZlatko Fras
AutorAmirhossein Sahebkar
AutorFrancesco Paneni
AutorManfredi Rizzo
AutorJohn Kastelein
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians' inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowering drugs, that not only allow for the effective reduction of LDL-C and do not increase the risk of new onset diabetes (NOD), and/or glucose impairment; in the opposite, some of them might effectively improve glucose control. One of the most interesting is pitavastatin, which is now available in Europe, with the best metabolic profile within statins (no risk of NOD, improvement of fasting blood glucose, HOMA-IR, HbA1c), bempedoic acid (with the potential for the reduction of NOD risk), innovative therapies-PCSK9 inhibitors and inclisiran with no DMT2 risk increase, and new forthcoming therapies, including apabetalone and obicetrapib-for the latter one with the possibility of even decreasing the number of patients diagnosed with prediabetes and DMT2. Altogether, nowadays we have possibility to individualize lipid lowering therapy in DMT2 patients and increase the number of patients on LDL-C goal without any risk of new onset diabetes and/or diabetes control worsening, and in consequence to reduce the risk of CVD complications due to progression of atherosclerosis in this patients' group.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCardiovascular Diabetology
Brojčani podacivol. 21, br. 1, 263
e-ISSN1475-2840
DOIhttps://doi.org/10.1186/s12933-022-01684-5
URN:NBNurn:nbn:hr:105:732007
Datum objave publikacije2022-11-28
URL dokumentahttps://cardiab.biomedcentral.com/articles/10.1186/s12933-022-01684-5
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-07-11 11:37:15